Korro Bio (KRRO) Accounts Payables (2018 - 2026)
Korro Bio's (KRRO) quarterly Accounts Payables came in at $2.0 million in Q1 2026, down 53.14% YoY from $4.2 million in Q1 2025, and up 18.53% on a QoQ basis from $1.7 million in Q4 2025.
Korro Bio (KRRO) Accounts Payables (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Accounts Payables data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Accounts Payables fell 53.14% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 53.14% YoY) and the FY2025 annual result came in at $1.7 million, down 58.64% from the prior year.
- Accounts Payables advanced to $2.0 million in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $7.3 million in Q4 2023 to a low of $338000.0 in Q3 2023.
- A 5-year average of $3.5 million and a median of $3.6 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables plunged 91.57% — and 2024, when it jumped 1660.36%.
- Tracing KRRO's Accounts Payables over 5 years: stood at $2.6 million in 2022, then soared by 179.46% to $7.3 million in 2023, then tumbled by 45.16% to $4.0 million in 2024, then sank by 58.64% to $1.7 million in 2025, then gained by 18.53% to $2.0 million in 2026.
- The last three Accounts Payables figures came in at $2.0 million (Q1 2026), $1.7 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.60 Mn |
| Mar 31, 2026 | 1.96 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 5.16 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Sep 30, 2024 | 5.95 Mn |
| Jun 30, 2024 | 5.69 Mn |
| Mar 31, 2024 | 4.66 Mn |
| Dec 31, 2023 | 7.28 Mn |
| Sep 30, 2023 | 338,000.00 |
| Jun 30, 2023 | 1.29 Mn |
| Mar 31, 2023 | 2.72 Mn |
| Dec 31, 2022 | 2.61 Mn |
| Sep 30, 2022 | 4.01 Mn |
| Jun 30, 2022 | 3.55 Mn |
| Mar 31, 2022 | 2.25 Mn |
| Dec 31, 2021 | 2.75 Mn |
| Sep 30, 2021 | 3.61 Mn |